GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Jun 10, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Jun 10, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, transaction-in-own-shares
TL;DR
GSK is buying back its own stock via Merrill Lynch.
AI Summary
On June 10, 2025, GSK plc announced its purchase of its own ordinary shares through its corporate stockbroker, Merrill Lynch International. The filing does not specify the number of shares purchased or the total dollar amount involved in these transactions.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine report of share transactions and does not contain significant new financial or operational information.
Key Players & Entities
- GSK plc (company) — Registrant
- Merrill Lynch International (company) — Corporate stockbroker
- June 2025 (date) — Reporting period
- June 10, 2025 (date) — Filing date
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K reports on GSK plc's transactions in its own shares during the month of June 2025.
Who is acting as GSK's stockbroker for these transactions?
Merrill Lynch International is acting as GSK's corporate stockbroker for these transactions.
Does the filing specify the number of shares GSK purchased?
No, the filing states that GSK has purchased shares but does not specify the number of ordinary shares purchased.
What is the nominal value of GSK's ordinary shares mentioned in the filing?
The ordinary shares are described as having a nominal value of 31 1/4 pence each.
What is GSK's principal executive office address?
GSK's principal executive office is located at 79 New Oxford Street, London, WC1A 1DG.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 10, 2025 regarding GSK plc (GLAXF).